Company intelligence / Profile preview

ASKA Pharmaceutical Holdings Co., Ltd.

Ownership: Private
Employees: ~762
Development stage: Commercial

Overview

ASKA specializes in hormonal therapies with a strong focus on women’s health, endocrinology, internal medicine, and urology. It holds a dominant share of the Japanese thyroid drug market (~96%) and has several late-stage clinical programs including first-in-class oral contraceptives and next-generation treatments for uterine fibroids/endometriosis.[4][5][9]

Therapeutic areas: GastroenterologyMen's HealthNephrologyEndocrinologyWomen's HealthOncology
Modalities: Small molecules (e.g., hormone agents, oral contraceptives, relugolix combination tablets)[6][10]Digital therapeutics[6]
Industry: Biotech

Drug pipeline

9 assets

AKP09

Preclinical

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ASKA Pharmaceutical Holdings Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASKA Pharmaceutical Holdings Co., Ltd..

Explore the full profile